Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Janssen Research & Development, LLC
Novartis
Hoffmann-La Roche
Bristol-Myers Squibb
Incyte Corporation
Oncolytics Biotech
Neonc Technologies, Inc.
Tizona Therapeutics, Inc
Hoffmann-La Roche
Cardiff Oncology
Incyte Corporation
Debiopharm International SA
Leap Therapeutics, Inc.
Sapience Therapeutics
Pierre Fabre Medicament
Inspirna, Inc.
IGM Biosciences, Inc.
Novartis
Karyopharm Therapeutics Inc
Cardiff Oncology
Boehringer Ingelheim
Cardiff Oncology
Biotheus Inc.
Merck Sharp & Dohme LLC
Biosplice Therapeutics, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Tesaro, Inc.
AbbVie
Eisai Inc.
Eisai Inc.
Shanghai Celfuture Biotech Co., Ltd.
AbbVie
Hoffmann-La Roche
Amgen
GC Biopharma Corp
Scandion Oncology A/S
Celyad Oncology SA
Mereo BioPharma
Mereo BioPharma
Amgen
Symphogen A/S
AB Science
Bionomics Limited
AbbVie
Amgen
Merck Sharp & Dohme LLC
Sanofi
AbbVie
Genentech, Inc.